| [1] |
Fitzmaurice C , et al. Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the Global Burden of Disease study[J]. JAMA Oncol, 2018,4(11):1553-1568.
|
| [2] |
European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer; EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2012,56(4):908-943.
|
| [3] |
Parkin DM, Bray F, Ferlay J , et al. Global cancer statistics, 2002[J]. CA Cancer J Clin, 2005,55:74-108.
|
| [4] |
Tanaka M, Katayama F, Kato H , et al. Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures[J]. J Epidemiol, 2011,21:401-416.
|
| [5] |
Llovet JM, Ricci S, Mazzaferro V , et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008,359:378-390.
|
| [6] |
Cheng AL, Guan Z, Chen Z , et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial[J]. Eur J Cancer, 2012,48:1452-1465.
|
| [7] |
Park JY, Ahn SH, Yoon YJ , et al. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma[J]. Cancer, 2007,110:129-137.
|
| [8] |
Ishikawa T, Imai M, Kamimura H , et al. Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a pilot study[J]. World J Gastroenterol, 2007,13:5465-5470.
|
| [9] |
Song MJ, Bae SH . Newer treatments for advanced hepatocellular carcinoma[J]. Korean J Intern Med, 2014,29:149-155.
|
| [10] |
Song MJ . Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma[J]. World J Gastroenterol, 2015,21:3843-3849.
|
| [11] |
Ando E, Tanaka M, Yamashita F , et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases[J]. Cancer, 2002,95:588-595.
|
| [12] |
Ueshima K, Kudo M, Takita M , et al. Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma[J]. Oncology, 2010,78:148-153.
|
| [13] |
Yamashita T, Arai K, Sunagozaka H , et al. Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma[J]. Oncology, 2011,81:281-290.
|
| [14] |
Obi S, Yoshida H, Toune R , et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion[J]. Cancer, 2006,106:1990-1997.
|
| [15] |
Yano H, Iemura A, Haramaki M , et al. Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines[J]. Hepatology, 1999,29:1708-1717.
|
| [16] |
Hamada A, Yamakado K, Nakatsuka A , et al. Hepatic arterial infusion chemotherapy with use of an implanted port system in patients with advanced hepatocellular carcinoma: prognostic factors[J]. J Vasc Interv Radiol, 2004,15:835-841.
|
| [17] |
Lin CP, Yu HC, Cheng JS , et al. Clinical effects of intra-arterial infusion chemotherapy with cisplatin, mitomycin C, leucovorin and 5-flourouracil for unresectable advanced hepatocellular carcinoma[J]. J Chin Med Assoc, 2004,67:602-610.
|
| [18] |
Hwang JY, Jang BK, Kwon KM , et al. Efficacy of hepatic arterial infusion therapy for advanced hepatocellular carcinoma using 5-fluorouracil, epirubicin and mitomycin-C[J]. Korean J Gastroenterol, 2005,45:118-124.
|
| [19] |
Woo HY, Bae SH, Park JY , et al. A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma[J]. Cancer Chemother Pharmacol, 2010,65:373-382.
|
| [20] |
Kim BK, Park JY, Choi HJ , et al. Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2011,137:659-667.
|
| [21] |
Nagano H, Kobayashi S, Marubashi S , et al. Combined IFN-α and 5-FU treatment as a postoperative adjuvant following surgery for hepatocellular carcinoma with portal venous tumor thrombus[J]. Exp Ther Med, 2013,5:3-10.
|
| [22] |
Nitta H, Beppu T, Imai K , et al. Adjuvant hepatic arterial infusion chemotherapy after hepatic resection of hepatocellular carcinoma with macroscopic vascular invasion[J]. World J Surg, 2013,37:1034-1042.
|
| [23] |
Kumamoto T, Tanaka K, Matsuo K , et al. Adjuvant hepatic arterial infusion chemotherapy with 5-Fluorouracil and interferon after curative resection of hepatocellular carcinoma: a preliminary report[J]. Anticancer Res, 2013,33:5585-5590.
|
| [24] |
Nishikawa H, Osaki Y, Kita R , et al. Transcatheter arterial infusion chemotherapy prior to radiofrequency thermal ablation for single hepatocellular carcinoma reduces the risk of intrahepatic distant recurrence[J]. Int J Oncol, 2012,41:903-909.
|
| [25] |
Ishikawa T, Kubota T, Abe S , et al. Hepatic arterial infusion chemotherapy with cisplatin before radical local treatment of early hepatocellular carcinoma (JIS score 0/1) improves survival[J]. Ann Oncol, 2014,25:1379-1384.
|
| [26] |
Sumie S, Yamashita F, Ando E , et al. Interventional radiology for advanced hepatocellular carcinoma: comparison of hepatic artery infusion chemotherapy and transcatheter arterial lipiodol chemoembolization[J]. AJR Am J Roentgenol, 2003,181:1327-1334.
|
| [27] |
Kim HY, Kim JD, Bae SH , et al. A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma[J]. Korean J Hepatol, 2010,16:355-361.
|
| [28] |
Nouso K, Miyahara K, Uchida D , et al. Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan[J]. Br J Cancer, 2013,109:1904-1907.
|
| [29] |
Tsai WL, Lai KH, Liang HL , et al. Hepatic arterial infusion chemotherapy for patients with huge unresectable hepatocellular carcinoma[J]. PLoS ONE, 2014, 13; 9:e92784.
|
| [30] |
Hiramine Y, Uto H, Imamura Y , et al. Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative study[J]. Exp Ther Med, 2011,2:433-441.
|
| [31] |
Song DS, Song MJ, Bae SH , et al. A comparative study between sorafenib and hepatic arterial infusion chemotherapy 31 for advanced hepatocellular carcinoma with portal vein tumor thrombosis[J]. J Gastroenterol 2015,50:445-454.
|
| [32] |
MinKe He, QiJiong Li, RuHai Zou, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion a randomized clinical trial. JAMA Oncol. 2019,5(7):953-960.
|
| [33] |
Sakon M, Nagano H, Dono K , et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches[J]. Cancer, 2002,94:435-442.
|
| [34] |
Ishikawa M, Kakizawa H, Hieda M , et al. Long-term outcomes of hepatic arterial port implantation using a coaxial microcatheter system in 176 patients with hepatocellular carcinoma[J]. Hiroshima J Med Sci, 2012,61:7-13.
|
